Nucor Corporation vs Novartis AG — how do they compare? Nucor Corporation trades at $269.38 (market cap $61.93B), while Novartis AG trades at $152.67 (market cap $295.37B). The key difference: Novartis AG is far larger — about 4.8× Nucor Corporation's market cap, and Novartis AG pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| NUE | NVS | |
|---|---|---|
Market Cap | $61.93B | $295.37B |
Sector | Basic Materials | Health |
52-Week High | $274.74 | $168.62 |
52-Week Low | $131.78 | $119.31 |
Enterprise Value | $66.34B | $336.69B |
Dividend Yield | 0.82% | 3.07% |
Signals from Pluang's Aura AI — not financial advice
Nucor (NUE) trades at $274.61, up 0.73% today, with a bullish technical outlook and strong earnings beats in Q1 and Q2 2026. The stock shows robust fundamentals with a P/E of 21.7 and net income margin of 7.99%, supported by record steel shipments and higher prices. Recent news highlights its position near buy points and resilience in industrial demand.
Outlook is positive with analyst consensus favoring buy ratings (59.37%) and a $279.63 price target. Risks include cyclical steel demand and tariff impacts, but earnings growth and institutional support provide upside potential for investors seeking exposure to industrial recovery.
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Trailing returns across standard periods
Latest headlines on both assets
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →